Combination treatment for large B-cell lymphoma that has returned
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a combination of four drugs (sonrotoclax, glofitamab, gemcitabine, and oxaliplatin) for people with large B-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of large B-cell lymphoma that has come back or did not respond to at least one previous treatment.
- You need to have at least one measurable tumor (a lymph node larger than 1.5 cm or another spot larger than 1 cm).
- You should be able to care for yourself (ECOG score 0-2).
- Your heart, kidney, liver, and blood cell counts must be within acceptable ranges.
- You cannot have lymphoma that has spread to the brain or spinal cord, or have had certain recent treatments like CAR T-cell therapy or stem cell transplants.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of three drugs (golcadomide, poseltinib, and rituximab) for people with diffuse large B-cell lymphoma that has returned or not responded to prior treatment. It may be an option if you cannot have a stem cell transplant.
This trial tests a combination of three drugs (mosunetuzumab, polatuzumab vedotin, and lenalidomide) for people with diffuse large B-cell lymphoma (a type of blood cancer) that has come back or not responded to previous treatment. The goal is to see if this combination is safe and effective.
This trial tests a new drug called glofitamab, combined with standard chemotherapy, for people whose large B-cell lymphoma came back or didn't respond to their first treatment. It aims to see if this combination works better than the usual approach.
This trial tests a combination of medicines (Pola-R-CHP plus a new drug called Sonrotoclax) for newly diagnosed aggressive B-cell lymphoma, especially cases with high BCL-2 protein or double-hit features. The goal is to see if adding Sonrotoclax helps control the cancer better.
This trial tests a new combination treatment for patients with large B-cell lymphoma who did not respond well to CAR-T cell therapy (a type of immunotherapy). The study uses tumor testing to guide which drugs to use, aiming to help patients whose cancer has stopped responding or is growing again.
This trial tests a combination of four drugs (homoharringtonine, a BCL-2 inhibitor, rituximab, and prednisone) for people with diffuse large B-cell lymphoma that has come back or not responded to earlier treatment. It aims to see if this new mix can help when standard therapies have stopped working.
Hear when a new High-grade B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.